209 related articles for article (PubMed ID: 37759736)
1. Cisplatin Dependent Secretion of Immunomodulatory High Mobility Group Box 1 (HMGB1) Protein from Lung Cancer Cells.
Gillespie KP; Pirnie R; Mesaros C; Blair IA
Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759736
[TBL] [Abstract][Full Text] [Related]
2. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells.
Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z
Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675
[TBL] [Abstract][Full Text] [Related]
3. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
[TBL] [Abstract][Full Text] [Related]
4. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer.
Jiao P; Hou J; Yao M; Wu J; Ren G
Biomed Pharmacother; 2019 Sep; 117():109164. PubMed ID: 31252267
[TBL] [Abstract][Full Text] [Related]
5. Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis.
Zhang R; Li Y; Wang Z; Chen L; Dong X; Nie X
Tumour Biol; 2015 Nov; 36(11):8585-92. PubMed ID: 26040768
[TBL] [Abstract][Full Text] [Related]
6. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
7. Activated protein C inhibits lipopolysaccharide-mediated acetylation and secretion of high-mobility group box 1 in endothelial cells.
Cai X; Biswas I; Panicker SR; Giri H; Rezaie AR
J Thromb Haemost; 2019 May; 17(5):803-817. PubMed ID: 30865333
[TBL] [Abstract][Full Text] [Related]
8. Elevated HMGB1 promotes the malignant progression and contributes to cisplatin resistance of non-small cell lung cancer.
Ma Y; Feng Q; Han B; Yu R; Jin Z
Hereditas; 2023 Jul; 160(1):33. PubMed ID: 37518006
[TBL] [Abstract][Full Text] [Related]
9. Peroxiredoxin-mediated disulfide bond formation is required for nucleocytoplasmic translocation and secretion of HMGB1 in response to inflammatory stimuli.
Kwak MS; Kim HS; Lkhamsuren K; Kim YH; Han MG; Shin JM; Park IH; Rhee WJ; Lee SK; Rhee SG; Shin JS
Redox Biol; 2019 Jun; 24():101203. PubMed ID: 31026770
[TBL] [Abstract][Full Text] [Related]
10. Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
Solari JIG; Filippi-Chiela E; Pilar ES; Nunes V; Gonzalez EA; Figueiró F; Andrade CF; Klamt F
BMC Cancer; 2020 May; 20(1):474. PubMed ID: 32456685
[TBL] [Abstract][Full Text] [Related]
11. Characterization and Quantification of Oxidized High Mobility Group Box 1 Proteoforms Secreted from Hepatocytes by Toxic Levels of Acetaminophen.
Pirnie R; Gillespie KP; Weng L; Mesaros C; Blair IA
Chem Res Toxicol; 2022 Oct; 35(10):1893-1902. PubMed ID: 35922039
[TBL] [Abstract][Full Text] [Related]
12. HMGB1 Enhances Drug Resistance and Promotes In Vivo Tumor Growth of Lung Cancer Cells.
Zheng H; Chen JN; Yu X; Jiang P; Yuan L; Shen HS; Zhao LH; Chen PF; Yang M
DNA Cell Biol; 2016 Oct; 35(10):622-627. PubMed ID: 27383136
[TBL] [Abstract][Full Text] [Related]
13. Autophagic secretion of HMGB1 from cancer-associated fibroblasts promotes metastatic potential of non-small cell lung cancer cells via NFκB signaling.
Ren Y; Cao L; Wang L; Zheng S; Zhang Q; Guo X; Li X; Chen M; Wu X; Furlong F; Meng Z; Xu K
Cell Death Dis; 2021 Sep; 12(10):858. PubMed ID: 34552063
[TBL] [Abstract][Full Text] [Related]
14. Redox state-dependent interaction of HMGB1 and cisplatin-modified DNA.
Park S; Lippard SJ
Biochemistry; 2011 Apr; 50(13):2567-74. PubMed ID: 21355578
[TBL] [Abstract][Full Text] [Related]
15. High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness.
Liu PL; Tsai JR; Hwang JJ; Chou SH; Cheng YJ; Lin FY; Chen YL; Hung CY; Chen WC; Chen YH; Chong IW
Am J Respir Cell Mol Biol; 2010 Nov; 43(5):530-8. PubMed ID: 19933377
[TBL] [Abstract][Full Text] [Related]
16. Immunological Significance of HMGB1 Post-Translational Modification and Redox Biology.
Kwak MS; Kim HS; Lee B; Kim YH; Son M; Shin JS
Front Immunol; 2020; 11():1189. PubMed ID: 32587593
[TBL] [Abstract][Full Text] [Related]
17. The repair capacity of lung cancer cell lines A549 and H1299 depends on HMGB1 expression level and the p53 status.
Yusein-Myashkova S; Stoykov I; Gospodinov A; Ugrinova I; Pasheva E
J Biochem; 2016 Jul; 160(1):37-47. PubMed ID: 26896489
[TBL] [Abstract][Full Text] [Related]
18. CAMSAP3-mediated regulation of HMGB1 acetylation and subcellular localization in lung cancer cells: Implications for cell death modulation.
Singharajkomron N; Seephan S; Iksen I; Chantaravisoot N; Wongkongkathep P; Hayakawa Y; Pongrakhananon V
Biochim Biophys Acta Gen Subj; 2024 Jun; 1868(6):130614. PubMed ID: 38598971
[TBL] [Abstract][Full Text] [Related]
19. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
20. Cancer-cell-secreted CXCL11 promoted CD8
Gao Q; Wang S; Chen X; Cheng S; Zhang Z; Li F; Huang L; Yang Y; Zhou B; Yue D; Wang D; Cao L; Maimela NR; Zhang B; Yu J; Wang L; Zhang Y
J Immunother Cancer; 2019 Feb; 7(1):42. PubMed ID: 30744691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
